Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Merck &
Nemtabrutinib is an orally available, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), including the wild-type enzyme and the C481S resistance mutant. It blocks B-cell receptor signaling and is studied in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06136559 | Phase 3 | Chronic Lymphocytic Leukemia | Recruiting | MRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CLLLeukemia, Chronic LymphocyticLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small LymphocyticSLLSmall-Cell Lymphoma
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →